Scarica l'app Stockscreener
1.33
5.00%
-0.07
Dopo l'orario di chiusura:
1.34
0.01
+0.75%
Precedente Chiudi:
$1.40
Aprire:
$1.4
Volume 24 ore:
536.59K
Relative Volume:
0.72
Capitalizzazione di mercato:
$171.14M
Reddito:
$514.70M
Utile/perdita netta:
$2.72M
Rapporto P/E:
-8.37
EPS:
-0.1589
Flusso di cassa netto:
$17.08M
1 W Prestazione:
-5.67%
1M Prestazione:
-20.36%
6M Prestazione:
-40.62%
1 anno Prestazione:
-68.56%
Intervallo 1D:
$1.32
$1.40
Intervallo di 1 settimana:
$1.32
$1.43
Portata 52W:
$1.32
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
Nome
Organogenesis Holdings Inc
Settore
Telefono
781-575-0775
Indirizzo
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
1.33 | 181.43M | 514.70M | 2.72M | 17.08M | -0.1589 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-28 | Iniziato | Lake Street | Buy |
| 2024-02-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-11-10 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-08-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-01-10 | Iniziato | SVB Leerink | Outperform |
| 2019-08-26 | Ripresa | Credit Suisse | Outperform |
| 2019-05-02 | Iniziato | Credit Suisse | Outperform |
| 2019-04-17 | Iniziato | Oppenheimer | Outperform |
| 2019-04-11 | Iniziato | SunTrust | Buy |
Mostra tutto
Organogenesis Holdings Inc Borsa (ORGO) Ultime notizie
Organogenesis Holdings stock falls 2.13 percent as Q2 revenue drops sharply - AD HOC NEWS
Undervalued Opportunities: Penny Stocks To Watch In September 2026 - simplywall.st
ORGO stock gains on a fresh price snapshot - AD HOC NEWS
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a Potential 47% Upside in Regenerative Medicine - DirectorsTalk Interviews
Organogenesis (ORGO) Drops 7% to $1.59: Wound Care Specialist Nears Critical SupportStop Loss Guidance - dars.gov.et
Organogenesis (ORGO) Slips 1.15% as Shares Consolidate Between Key Support and ResistanceNHNL Ratio - dars.gov.et
ORGO Q2 2026 Earnings: Significant EPS Miss Highlights Profitability ChallengesDiluted EPS Report - careplusvn.com
Organogenesis stock trades without a fresh catalyst, recent results define the picture - ad-hoc-news.de
Organogenesis (ORGO) Quarter in Focus: Reported EPS Misses Expectations for the Current Session; Closing Reaction - vinanet.vn
ORGO | Organogenesis Holdings Inc. Class FinancialsRevenue Breakdown - Quiver Quantitative
Organogenesis (ORGO) Shares: Moves 2.17% Down to $1.80 in the Latest Session; Chart View - dars.gov.et
Spotlighting Anixa Biosciences And 2 Other Noteworthy Penny Stocks - Sahm
Organogenesis (ORGO) Chart: Moves 3.35% Up to $1.85 on the Day; Current Setup: the Near-Term Reference Band Stretches From $1.76 to $1.94 in Latest TradingRSI Overbought Alerts - vinanet.vn
Organogenesis Holdings Inc (ORGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ORGO Advances 1.70% to $1.79 as Organogenesis Holds Key Support ZoneThrowback Trade - dars.gov.et
Organogenesis (ORGO) Q2 2026 Earnings Call Transcript - AOL.com
Oragenics: Q2 Earnings Snapshot - AOL.com
Organogenesis, lured to RI with tax credits, is bleeding money - The Business Journals
OrganiGram: Fiscal Q3 Earnings Snapshot - AOL.com
Organogenesis Holdings, Inc. Class A Revenue Breakdown – MUN:2PQ - TradingView
Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution - Yahoo Finance
Organogenesis Holdings Inc (ORGO) Stock News Today - TradingKey
Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed? - Yahoo Finance
Organogenesis (NASDAQ:ORGO) Cut to Strong Sell at Wall Street Zen - MarketBeat
Organogenesis Shares Plunge After Revenue Slump, Wider Loss and Lower Outlook - Moomoo
Truist Adjusts Price Target on Organogenesis to $2 From $3, Maintains Hold Rating - marketscreener.com
Truist Financial Has Lowered Expectations for Organogenesis (NASDAQ:ORGO) Stock Price - MarketBeat
Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Organogenesis Q2 2026 miss sends shares lower By Investing.com - Investing.com Australia
Form 8K Organogenesis Holdings Inc For: 6 August By Investing.com - Investing.com Nigeria
Organogenesis Holdings enters at-the-market sales agreement for up to $75 million - Investing.com Nigeria
Organogenesis Holdings Inc. (ORGO) Stock Analysis: Potential 24% Upside For Investors - DirectorsTalk Interviews
Organogenesis Q2 Earnings Call Highlights - Yahoo Finance
[ORGO] Q2 2026 Earnings: Deep EPS Miss Sends Shares Down 22.8%Full Year Guidance - dars.gov.et
Organogenesis earnings missed by $0.42, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Organogenesis Q2 2026 miss sends shares lower - Investing.com
Transcript : Organogenesis Holdings Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
Organogenesis: Q2 Earnings Snapshot - Barchart.com
Organogenesis Holdings Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
ORGO: Q2 2026 revenue plunged 58% and net loss widened sharply amid ongoing market and regulatory challenges - TradingView
Organogenesis (Nasdaq: ORGO) sets up $75M at-the-market stock sale - Stock Titan
Organogenesis Holdings Inc. Q2 2026: Revenue $42.8M, EPS $(0.77) — 10-Q Summary - tradingview.com
Organogenesis (NASDAQ: ORGO) hit by 58% sales drop and $149M first-half loss - Stock Titan
Organogenesis Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results - The Manila Times
Organogenesis Holdings reports Q2 2026 revenue $42.8M, net loss $96.3M - TradingView
Organogenesis Holdings Inc. Revises Revenue Guidance for the Second Half of the Year Ending December 31, 2026 - marketscreener.com
Organogenesis Holdings, Inc. Class A Revenue Breakdown – LS:A2PA31 - TradingView
Organogenesis Q2 2026 earnings: Revenue falls 58% as losses widen - TradingKey
ORGO Q2'26 Earnings: EPS estimate is (0.35) USD - TradingView
Organogenesis Holdings Inc. expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Organogenesis Holdings Inc Azioni (ORGO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Organogenesis Holdings Inc Azioni (ORGO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Driscoll Michael Joseph | Director |
Mar 09 '26 |
Buy |
2.67 |
10,000 |
26,688 |
225,707 |
| NUSSDORF GLENN H | Director |
Dec 16 '25 |
Sale |
5.14 |
200,000 |
1,027,060 |
2,565,591 |
1.15%
5.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):